Wolters Kluwer NV
amsterdam : WLSN

November 09, 2011 04:16 ET

Wolters Kluwer Reaches Definitive Agreement to Sell Its Pharma-Related Marketing & Publishing Services Business to Springer

ALPHEN AAN DEN RIJN, NETHERLANDS--(Marketwire - Nov 9, 2011) -


Division Will Focus on High Growth Clinical Markets

Alphen aan den Rijn, the Netherlands (November 9, 2011) - Wolters Kluwer, a market-leading global information services company focused on professionals, today announced that it has signed a definitive agreement to sell its pharma- related Marketing & Publishing Services business to Springer. The announcement follows an earlier announcement by Wolters Kluwer in July that it planned to divest its pharma-related assets. The transaction is subject to customary closing conditions, including regulatory approvals.

"The sale of our pharma-related business is part of our strategy to focus on our core health markets and accelerate growth by providing innovative solutions to clinicians globally," said Nancy McKinstry, CEO and Chairman of the Executive Board of Wolters Kluwer.

The agreement encompasses the Marketing & Publishing Services business unit, part of the Wolters Kluwer Health & Pharma Solutions division. Marketing & Publishing Services is a leading global provider of strategic marketing, publishing, and business intelligence products and services to the pharmaceutical industry as well as to medical libraries and academic and research institutions. The sale represents approximately 35% of the company's pharma-related assets in terms of revenue, with Adis and inScience Communications as the leading brands, and encompasses approximately 450 employees globally.

"This is an exciting time for our business in terms of opportunities," added Bob Becker, CEO and President of Wolters Kluwer Health & Pharma Solutions. "We believe that Springer is the best fit for housing the Marketing & Publishing Services business going forward and I want to express our great appreciation to the Marketing & Publishing Services employees and wish them all the best for the future."

The proceeds from this divestment are expected to be used for general corporate purposes including the reduction of debt levels in line with the company's stated objectives and investments in the business.

For more information on Wolters Kluwer Health, visit www.wolterskluwerhealth.com. For more information on Pharma Solutions, visit www.wolterskluwerpharma.com.

About Wolters Kluwer

Wolters Kluwer is a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer's leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer had 2010 annual revenues of EUR3.6 billion, employs approximately 19,000 people worldwide, and maintains operations across Europe, North America, Asia Pacific, and Latin America, serving customers globally. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.

Visit our website, YouTube, follow @Wolters_Kluwer on Twitter, or look up Wolters Kluwer on Facebook for more for information about our customers, market positions, brands, and organization.

Should you wish to change how you receive information from Wolters Kluwer, please click here.

Forward-looking Statements

This press release contains forward-looking statements. These statements may be identified by words such as "expect", "should", "could", "will", "shall" and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events, or otherwise.

PDF version of Press Release: http://hugin.info/130682/R/1562280/483934.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Wolters Kluwer NV via Thomson Reuters ONE

[HUG#1562280]

Contact Information

  • Contact:
    Caroline Wouters
    Vice President,
    Corporate Communications
    Wolters Kluwer
    + 31 (0)172 641 459
    Email Contact

    Robert Dekker
    Vice President, Communications
    Wolters Kluwer
    Health & Pharma Solutions
    +1 (215) 521 8928
    Email Contact

    Jon Teppo
    Vice President,
    Investor Relations
    Wolters Kluwer
    + 31 (0)172 641 407
    Email Contact